Frontiers in Immunology,
Год журнала:
2022,
Номер
13
Опубликована: Июнь 3, 2022
The
coronavirus
disease
2019
(COVID-19)
pandemic
has
turned
pregnant
women’s
healthcare
into
a
worldwide
public
health
challenge.
Although
initial
data
did
not
demonstrate
pregnancy
as
more
susceptible
period
to
severe
outcomes
of
acute
respiratory
syndrome-related
2
(SARS-CoV-2)
infection,
there
are
an
increasing
number
reports
showing
that
only
women
might
be
at
significantly
higher
risk
than
non-pregnant
by
COVID-19
but
also
the
fetus.
These
findings
may
related
adaptive
changes
occur
during
pregnancy,
such
reduction
in
residual
capacity,
decrease
viral
immune
responses,
and
increased
for
thromboembolic
events.
Additionally,
despite
SARS-CoV-2
vertical
transmission
evidence
being
uncommon,
maternal
illness
severity
reflect
serious
perinatal
neonatal
outcomes.
Thus,
protecting
maternal–fetal
dyad
against
is
critical.
Even
though
initially
were
excluded
from
vaccine
trials,
several
studies
have
provided
safety
efficacy
overall
platforms.
Vaccination
becomes
priority
can
generate
benefits
both
mother
newborn:
neutralizing
antibodies
transmitted
through
placenta
breastfeeding.
Moreover,
regarding
passive
immunization,
human
milk
contains
other
bioactive
molecules
cells
able
modulate
newborn’s
response,
which
amplified
after
vaccine.
Nonetheless,
many
issues
remain
elucidated,
considering
magnitude
protective
immunity
transferred,
duration
induced
immunity,
optimal
interval
immunization.
In
this
review,
we
assessed
these
unmet
topics
supported
literature
vaccine’s
immunogenicity,
heterogeneity,
unique
antiviral
features.
Immunobridging
is
an
important
methodology
that
can
be
used
to
extrapolate
vaccine
efficacy
estimates
populations
not
evaluated
in
clinical
studies,
and
has
been
successfully
developing
many
vaccines.
Dengue,
caused
by
a
mosquito-transmitted
flavivirus
endemic
tropical
subtropical
regions,
traditionally
thought
of
as
pediatric
disease
but
now
global
threat
both
children
adults.
We
bridged
immunogenicity
data
from
phase
3
study
tetravalent
dengue
(TAK-003),
performed
adolescents
living
areas,
with
adults
non-endemic
areas.
Neutralizing
antibody
responses
were
comparable
studies
following
receipt
two-dose
TAK-003
schedule
(months
0
3).
Similar
immune
observed
across
exploratory
assessments
additional
humoral
responses.
These
support
the
potential
for
Enfermedades infecciosas y microbiologia clinica (English ed ),
Год журнала:
2025,
Номер
43(1), С. 36 - 46
Опубликована: Янв. 1, 2025
Despite
high
initial
vaccination
rates,
Spain's
current
COVID-19
coverage
in
recommended
groups
does
not
meet
WHO
targets.
For
the
upcoming
season,
challenges
include
revising
age,
updating
risk
groups,
and
unifying
criteria
with
flu
vaccine
co-administration.
European
Commission's
advance
purchase
agreements
limit
access
to
certain
vaccines,
need
for
vaccines
effective
against
variants
adds
administrative
complexities.
recommendations
should
adapt
these
specific
circumstances.
Using
predominant
appropriate
response
duration
is
crucial
protect
at-risk
populations.
Enhancing
training
health
education
campaigns
professionals
general
public,
alongside
utilizing
tools
simplify
recommendations,
can
promote
higher
rates
Spain.
Addressing
essential
ensure
adequate
protection
improve
coverage,
ultimately
achieving
better
public
outcomes
face
of
evolving
threats.
British Journal of Clinical Pharmacology,
Год журнала:
2022,
Номер
89(1), С. 114 - 149
Опубликована: Окт. 3, 2022
Severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)-induced
COVID-19
is
a
complicated
disease.
Clinicians
are
continuously
facing
difficulties
to
treat
infected
patients
using
the
principle
of
repurposing
drugs
as
no
specific
available
COVID-19.
To
minimize
severity
and
mortality,
global
vaccination
only
hope
potential
preventive
measure.
After
year-long
research
clinical
struggle,
165
vaccine
candidates
have
been
developed
some
currently
still
in
pipeline.
A
total
28
candidate
vaccines
approved
for
use
remainder
different
phases
trials.
In
this
comprehensive
report,
authors
aim
demonstrate,
classify
provide
up-to-date
trial
status
all
discovered
date
specifically
focus
on
candidates.
Finally,
focused
types
medically
distinct
populations.
Frontiers in Immunology,
Год журнала:
2022,
Номер
13
Опубликована: Июнь 3, 2022
The
coronavirus
disease
2019
(COVID-19)
pandemic
has
turned
pregnant
women’s
healthcare
into
a
worldwide
public
health
challenge.
Although
initial
data
did
not
demonstrate
pregnancy
as
more
susceptible
period
to
severe
outcomes
of
acute
respiratory
syndrome-related
2
(SARS-CoV-2)
infection,
there
are
an
increasing
number
reports
showing
that
only
women
might
be
at
significantly
higher
risk
than
non-pregnant
by
COVID-19
but
also
the
fetus.
These
findings
may
related
adaptive
changes
occur
during
pregnancy,
such
reduction
in
residual
capacity,
decrease
viral
immune
responses,
and
increased
for
thromboembolic
events.
Additionally,
despite
SARS-CoV-2
vertical
transmission
evidence
being
uncommon,
maternal
illness
severity
reflect
serious
perinatal
neonatal
outcomes.
Thus,
protecting
maternal–fetal
dyad
against
is
critical.
Even
though
initially
were
excluded
from
vaccine
trials,
several
studies
have
provided
safety
efficacy
overall
platforms.
Vaccination
becomes
priority
can
generate
benefits
both
mother
newborn:
neutralizing
antibodies
transmitted
through
placenta
breastfeeding.
Moreover,
regarding
passive
immunization,
human
milk
contains
other
bioactive
molecules
cells
able
modulate
newborn’s
response,
which
amplified
after
vaccine.
Nonetheless,
many
issues
remain
elucidated,
considering
magnitude
protective
immunity
transferred,
duration
induced
immunity,
optimal
interval
immunization.
In
this
review,
we
assessed
these
unmet
topics
supported
literature
vaccine’s
immunogenicity,
heterogeneity,
unique
antiviral
features.
